澳洲代写论文之基因专利一
介绍
本文将讨论是否应该被授予专利权的人类和其他基因和蛋白质的性质，从ABC新闻文章里程碑意义的裁决，认为癌基因专利无效“的问题。
里程碑意义的裁决认为癌基因专利无效
本文提及的情况下，Myriad Genetics公司的专利拥有者的乳腺癌和卵巢癌基因BRCA1和BRCA2收费约3700亿美元的考验，一个女人是否更容易受到乳腺癌和卵巢癌的美国公民自由联盟（ACLU ）。该公司还表示，澳大利亚院校的测试，以知识产权权利不征收特许权使用费，同时在澳大利亚基因技术有限公司运行测试。
“测试是一种”发现“，而不是”发明“的任何专利无效”中提到的Sweet法官形成了纽约地区法院。
澳洲代写论文之Gene Patents （Part 1）
Introduction
This essay will discuss the issue about whether patents should be awarded on human and other genes and proteins found in nature which from the ABC News article ‘Landmark ruling deems cancer gene patents invalid’.
Landmark ruling deems cancer gene patents invalid
This article mention the case that Myriad Genetics the patent owner of the breast and ovarian cancer genes BRCA1 and BRCA2 charge around 3,700 US dollar for the test of whether a woman is more susceptible to developing breast and ovarian cancer from the American Civil Liberties Union (ACLU). It also said that the intellectual property right of test to Australian institutions does not impose royalties; meanwhile the Genetic Technologies Limited runs the tests in Australia.
“The test is a kind of ‘discovery’ instead of ‘invention’ which making any patent invalid” mentioned by the Judge Sweet form the New York district court.
